TVRD - חוב כולל להון Cara Corp

Cara Therapeutics Inc (TVRD) is developing treatments for pruritus associated with nephropathy, leveraging strategic alliances and patent acquisitions to create sales synergies. In partnership with Vifor Pharma, the company is introducing innovations to global markets. Financial success relies on the commercial launch of products in specialized US centers, disregarding macroeconomic factors. This chart on GURU.Markets confirms these data, where the total debt-to-equity ratio stands at 0.02.

Total debt-to-equity measures the proportion of borrowed funds within the financing structure, determining the business's level of dependence on external creditors. Investors evaluate the debt load using the total debt-to-equity ratio to analyze financial stability. An increase in this metric signals a risk of insolvency. For Cara Therapeutics Inc (TVRD), this is critical due to R&D cuts and a liquidity shortage. The current balance sheet structure reflects a struggle for survival amid clinical trial failures.